GAETANI, LORENZO
 Distribuzione geografica
Continente #
NA - Nord America 1.144
EU - Europa 631
AS - Asia 430
OC - Oceania 5
SA - Sud America 5
AF - Africa 4
Totale 2.219
Nazione #
US - Stati Uniti d'America 1.143
IE - Irlanda 213
SG - Singapore 182
IT - Italia 168
HK - Hong Kong 145
CN - Cina 75
SE - Svezia 59
FI - Finlandia 33
DE - Germania 29
RU - Federazione Russa 20
UA - Ucraina 18
CZ - Repubblica Ceca 17
RO - Romania 17
FR - Francia 14
BE - Belgio 12
GB - Regno Unito 9
KR - Corea 9
NL - Olanda 9
JP - Giappone 5
NZ - Nuova Zelanda 5
VN - Vietnam 5
AT - Austria 4
EG - Egitto 4
GR - Grecia 4
BR - Brasile 3
CO - Colombia 2
IN - India 2
IR - Iran 2
PL - Polonia 2
UZ - Uzbekistan 2
CA - Canada 1
CH - Svizzera 1
ES - Italia 1
LB - Libano 1
SK - Slovacchia (Repubblica Slovacca) 1
TR - Turchia 1
TW - Taiwan 1
Totale 2.219
Città #
Chandler 254
Dublin 213
Hong Kong 144
Singapore 143
Boardman 122
San Mateo 65
Perugia 60
Altamura 59
Des Moines 42
Lawrence 39
Medford 39
Princeton 39
Andover 38
Ann Arbor 38
Ashburn 34
Wilmington 34
Beijing 26
Redmond 24
Helsinki 21
Redwood City 18
Los Angeles 16
Falls Church 13
Brno 12
Brussels 12
Munich 11
Timisoara 10
Houston 9
Seoul 9
Amsterdam 8
Fairfield 7
Rome 7
Bucharest 6
Dallas 6
Lappeenranta 6
Norwalk 6
Saint Petersburg 6
Seattle 6
Auckland 5
Dong Ket 5
Tokyo 5
Woodbridge 5
Chicago 4
Milan 4
Santa Clara 4
Giza 3
Moscow 3
Olomouc 3
Bogotá 2
Brixen 2
Cambridge 2
Foligno 2
Guangzhou 2
Jacksonville 2
New York 2
San Paolo di Civitate 2
Turin 2
Vienna 2
Alviano 1
Anshan 1
Baltimore 1
Bollebygd 1
Brookfield 1
Böblingen 1
Chiaravalle 1
Curitiba 1
Dearborn 1
Elk Grove Village 1
Florence 1
Frankfurt am Main 1
Fremont 1
Groningen 1
Harbin 1
Hsinchu 1
Izmir 1
Kolkata 1
Madrid 1
Mogi Guacu 1
Monselice 1
Montreuil 1
Mumbai 1
Nanjing 1
Napoli 1
Nuremberg 1
Paris 1
Parma 1
Radeberg 1
Secaucus 1
Shanghai 1
Shenyang 1
Shibin al Kawm 1
Suzhou 1
Tappahannock 1
Teresina 1
Tulsa 1
Vancouver 1
Wuhan 1
Totale 1.702
Nome #
CSF and blood biomarkers for Parkinson's disease 117
Synaptic plasticity and experimental autoimmune encephalomyelitis: implications for multiple sclerosis 93
Microglial activation and the nitric oxide/cGMP/PKG pathway underlie enhanced neuronal vulnerability to mitochondrial dysfunction in experimental multiple sclerosis 80
CSF and Blood Biomarkers in Neuroinflammatory and Neurodegenerative Diseases: Implications for Treatment 71
A new enzyme-linked immunosorbent assay for neurofilament light in cerebrospinal fluid: analytical validation and clinical evaluation 67
Visual pathway involvement in multiple sclerosis: Look straight in the eyes 62
Cerebrospinal fluid free light chains compared to oligoclonal bands as biomarkers in multiple sclerosis 59
Lower urinary tract symptoms and urodynamic dysfunction in clinically isolated syndromes suggestive of multiple sclerosis 58
2017 revisions of McDonald criteria shorten the time to diagnosis of multiple sclerosis in clinically isolated syndromes 57
Extracranial Venous Drainage Pattern in Multiple Sclerosis and Healthy Controls: Application of the 2011 Diagnostic Criteria for Chronic Cerebrospinal Venous Insufficiency 56
Treatment of multiple sclerosis relapses with high-dose methylprednisolone reduces the evolution of contrast-enhancing lesions into persistent black holes 53
Positive allosteric modulation of indoleamine 2,3-dioxygenase 1 restrains neuroinflammation 52
Cerebrospinal fluid neurofilament light chain tracks cognitive impairment in multiple sclerosis 50
Retinopathy during interferon-β treatment for multiple sclerosis: case report and review of the literature 48
Molecular profiling in Parkinsonian syndromes: CSF biomarkers 46
High risk of early conversion to multiple sclerosis in clinically isolated syndromes with dissemination in space at baseline 46
Recurrent hyperCKemia with normal muscle biopsy in a pediatric patient with neuromyelitis optica 44
Host and Microbial Tryptophan Metabolic Profiling in Multiple Sclerosis 44
Cognitive impairment in multiple sclerosis: lessons from cerebrospinal fluid biomarkers 44
Cerebrospinal fluid and serum D-serine concentrations are unaltered across the whole clinical spectrum of Alzheimer's disease 41
Tracing Neurological Diseases in the Presymptomatic Phase: Insights From Neurofilament Light Chain 41
Serum neurofilament light chain as a preclinical marker of neurodegeneration 40
The Challenge of Disease-Modifying Therapies in Parkinson's Disease: Role of CSF Biomarkers. 39
Multiple sclerosis and chronic progressive external ophthalmoplegia associated with a large scale mitochondrial DNA single deletion 38
Cerebrospinal fluid neurofilament light chain predicts disease activity after the first demyelinating event suggestive of multiple sclerosis 38
Cerebrospinal fluid levels of proenkephalin and prodynorphin are differentially altered in Huntington's and Parkinson's disease 37
Infliximab monotherapy for neuro-Behçet's disease: a case report 37
Synaptic dysfunction in multiple sclerosis: A red thread from inflammation to network disconnection 37
A blood test for Alzheimer's disease: a step forward 36
Author Response: NfL as Analogue of C-Reactive Protein in Neurologic Diseases: Instructions for Use 35
High performance liquid chromatography determination of L-glutamate, L-glutamine and glycine content in brain, cerebrospinal fluid and blood serum of patients affected by Alzheimer's disease 35
Interleukin-17 affects synaptic plasticity and cognition in an experimental model of multiple sclerosis 35
Neurofilament light chain as a biomarker in neurological disorders 33
Finding a way to preserve mitochondria: New pathogenic pathways in experimental multiple sclerosis 33
Neuroinflammation and Alzheimer's Disease: A Machine Learning Approach to CSF Proteomics 33
Defining the course of tumefactive multiple sclerosis: A large retrospective multicentre study 32
Psychiatric symptoms in multiple sclerosis: a biological perspective on synaptic and network dysfunction 31
The no evidence of disease activity (NEDA) concept in MS: impact of spinal cord MRI 31
Headache and immunological/autoimmune disorders: a comprehensive review of available epidemiological evidence with insights on potential underlying mechanisms 31
Cerebrospinal fluid β-synuclein as a synaptic biomarker for preclinical Alzheimer's disease 30
Blood biomarkers may distinguish among dementia disorders 28
Insights into the pathophysiology of psychiatric symptoms in central nervous system disorders: Implications for early and differential diagnosis 28
α-Synuclein Seed Amplification Assays for Diagnosing Synucleinopathies: The Way Forward 28
CSF neurochemical profile and cognitive changes in Parkinson's disease with mild cognitive impairment 25
Phosphatidylethanolamine Binding Protein 1 (PEBP1) in Alzheimer's Disease: ELISA Development and Clinical Validation 25
Impact of post-contrast MRI in the definition of active multiple sclerosis 23
Alpha and Beta Synucleins: From Pathophysiology to Clinical Application as Biomarkers 22
Machine Learning Driven Profiling of Cerebrospinal Fluid Core Biomarkers in Alzheimer's Disease and Other Neurological Disorders 20
Clinical correlates of state and trait anxiety in multiple sclerosis 20
LRRK2 Quantification in Cerebrospinal Fluid of Patients with Parkinson's Disease and Atypical Parkinsonian Syndromes 16
CSF Synaptic Biomarkers in AT(N)-Based Subgroups of Lewy Body Disease 16
Potential diagnostic value of CSF metabolism-related proteins across the Alzheimer's disease continuum 15
Association between Neuropsychological Performance and CSF Profile in Subjective Cognitive Decline: Towards the Diagnosis of Preclinical AD 15
Investigating alpha-synuclein co-pathology in Alzheimer's disease by means of cerebrospinal fluid alpha-synuclein seed amplification assay 14
Fully automated measurement of plasma Aβ42/40 and p-tau181: Analytical robustness and concordance with cerebrospinal fluid profile along the Alzheimer's disease continuum in two independent cohorts 14
Post-contrast MRI in multiple sclerosis: Towards a judicious use of gadolinium-based contrast agents 14
CSF and plasma Aβ42/40 across Alzheimer's disease continuum: comparison of two ultrasensitive Simoa® assays targeting distinct amyloid regions 13
Methods to discover and validate biofluid-based biomarkers in neurodegenerative dementias 13
Trajectories of CSF and plasma biomarkers across Alzheimer's disease continuum: Disease staging by NF-L, p-tau181, and GFAP 12
Clinical and diagnostic implications of Alzheimer's disease copathology in Lewy body disease 12
A microbially produced AhR ligand promotes a Tph1-driven tolerogenic program in multiple sclerosis 11
The Immune Signature of CSF in Multiple Sclerosis with and without Oligoclonal Bands: A Machine Learning Approach to Proximity Extension Assay Analysis 11
Diagnostic value of kappa free light chain index in patients with primary progressive multiple sclerosis – a multicentre study 10
Required improvements for cerebrospinal fluid-based biomarker tests of Alzheimer's disease 10
SARS-CoV-2 vaccines tolerability: A perspective by people with multiple sclerosis 9
Intrathecal B cell activation and memory impairment in multiple sclerosis 7
Biomarker-Based Prediction of Parkinson Disease: Time for a Shift in Neurologists' Attitude Toward Neurodegenerative Diseases 7
Hippocampal neuroplasticity and inflammation: Relevance for multiple sclerosis 7
CSF neurosecretory proteins VGF and neuroserpin in patients with Alzheimer's and Lewy body diseases 6
Totale 2.341
Categoria #
all - tutte 12.472
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 12.472


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020108 0 0 0 0 2 2 1 15 7 22 21 38
2020/2021157 3 4 4 1 72 17 7 20 11 5 6 7
2021/2022372 3 46 12 12 25 10 5 91 17 46 61 44
2022/2023843 44 184 15 67 62 102 4 36 294 1 25 9
2023/2024505 24 53 15 11 7 2 95 20 68 25 78 107
2024/2025282 13 107 68 75 19 0 0 0 0 0 0 0
Totale 2.341